<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925000</url>
  </required_header>
  <id_info>
    <org_study_id>TLC178A1001</org_study_id>
    <nct_id>NCT02925000</nct_id>
  </id_info>
  <brief_title>Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy</brief_title>
  <official_title>A Phase I/IIa, Open Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Liposome Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Liposome Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/IIa, Open label, Dose-escalation Study Investigating the Safety,&#xD;
      Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in&#xD;
      Patients with Advanced Malignancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol No: TLC178A1001&#xD;
&#xD;
      Name of Finished Product: LipoVNB (Liposomal Vinorelbine Tartrate)&#xD;
&#xD;
      Title of Study:&#xD;
&#xD;
      Phase I/IIa, Open label, Dose-escalation Study Investigating the Safety, Tolerability, and&#xD;
      Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with&#xD;
      Advanced Malignancy.&#xD;
&#xD;
      Study duration:&#xD;
&#xD;
      Every patient will have a treatment period of 4-week cycles until completion of 6 cycles,&#xD;
      progression of disease or intolerance, withdrawal of consent or Investigator's judgment,&#xD;
      whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Actual">October 6, 2020</completion_date>
  <primary_completion_date type="Actual">October 6, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) determination</measure>
    <time_frame>4 weeks</time_frame>
    <description>To determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) ofintravenous LipoVNB given every 4 weeks (Q4W) in patients with advanced malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of AUC (0-inf) calculated by plasma concentration of vinorelbine[</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Area under the plasma concentration time curve from zero (predose) extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of AUC (0-inf) calculated by plasma concentration of majormetabolite, 4-O-deacetylvinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Area under the plasma concentration time curve from zero (predose) extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of AUC(0 - last) calculated by plasma concentration ofvinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Area under the plasma concentration time curve from zero (predose) to the time of the lastquantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of AUC(0 - last) calculated by plasma concentration of majormetabolite, 4-O-deacetylvinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Area under the plasma concentration time curve from zero (predose) to the time of the lastquantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of Cmax calculated by plasma concentration of vinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Maximum plasma concentration observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of tmax calculated by plasma concentration of vinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of tmax calculated by plasma concentration of major metabolite,4-O-deacetylvinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of t1/2 calculated by plasma concentration of vinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Apparent terminal half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of t1/2 calculated by plasma concentration of 4-O-deacetylvinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Apparent terminal half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of MRT(0-inf) calculated by plasma concentration of vinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Mean residence time extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of MRT(0-inf) calculated by plasma concentration of 4-O-deacetylvinorelbine</measure>
    <time_frame>from day 1 to day 29</time_frame>
    <description>Mean residence time extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose exposure relationship in patients with advanced malignancies treated with single and multipledoses of LipoVNB</measure>
    <time_frame>up to 6 months</time_frame>
    <description>single and multiple dose effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>up to 6 months</time_frame>
    <description>treatment related AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>TEAE percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LipoVNB antitumor activity assessed by response rate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>antitumor response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LipoVNB antitumor activity assessed by duration of response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) of patients with advanced malignancies treated with LipoVNB</measure>
    <time_frame>up to 6 months</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>TLC178</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Vinorelbine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLC178</intervention_name>
    <description>TLC178</description>
    <arm_group_label>TLC178</arm_group_label>
    <other_name>Liposomal Vinorelbine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male or female, ≥18 years of age (≥20 years of age in Taiwan)&#xD;
&#xD;
          -  Patients with histologically/cytologically confirmed solid tumor, or lymphoma&#xD;
             including PTCL or CTCL.&#xD;
&#xD;
          -  Malignancies for which there is no standard therapy, or previously treated locally&#xD;
             advanced, refractory/relapsed or metastatic disease for which local curative surgery,&#xD;
             curable radiotherapy, or satisfactory systemic anticancer therapy is no longer&#xD;
             available&#xD;
&#xD;
          -  Having at least one measurable tumor&#xD;
&#xD;
          -  ECOG Performance Status of ≤2&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patient with untreated or inadequate controlled brain metastases.&#xD;
&#xD;
          -  Prior systemic standard or investigational anticancer therapy, including target&#xD;
             therapy, chemotherapy, immunotherapy within 28 days prior to the first dose of study&#xD;
             drug. The above mentioned conditions which the Investigator considers there is no more&#xD;
             drug effect, such as ≥5 half-lives are permitted&#xD;
&#xD;
          -  Prior radiotherapy within 4 weeks before screening&#xD;
&#xD;
          -  Prior autologous stem cell transplantation within 3 months of screening and allogeneic&#xD;
             stem cell transplantation within 6 months of screening&#xD;
&#xD;
          -  More than 5 lines of previous cytotoxic therapies. For patients of CTCL who failed&#xD;
             romidepsin, more than 4 lines of previous therapies&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to first administration of study drug&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina or severe congestive heart failure&#xD;
             (New York Heart Classification Class IV) or major stroke within 3 months prior to&#xD;
             screening period&#xD;
&#xD;
          -  Medical history of uncontrolled but clinically significant abnormal cardiac conduction&#xD;
             abnormalities at electrocardiogram (ECG) at screening, any history or evidence of long&#xD;
             QT syndrome or QTcF interval &gt;450 msec for males and &gt;470 msec for females (according&#xD;
             to Fridericia's correction) at screening&#xD;
&#xD;
          -  Known HIV infection; active hepatitis B or C without concurrent treatment&#xD;
&#xD;
          -  Coexistence of any active and uncontrolled infection&#xD;
&#xD;
          -  Poor vital organ function defined&#xD;
&#xD;
          -  Uncontrolled and unstable concurrent medical condition including psychiatric disorders&#xD;
             and alcohol/substance dependence/abuse that will jeopardize the safety of the patient,&#xD;
             interfere with the objectives of the study, or affect the patient compliance with&#xD;
             study requirements, as determined by the Investigator&#xD;
&#xD;
          -  Known allergy or hypersensitivity to the study drug or its components&#xD;
&#xD;
          -  Use of strong inhibitors or inducers of cytochrome P450 enzymes CYP3A4&#xD;
&#xD;
          -  Pregnant or breast feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Brown</last_name>
    <role>Study Director</role>
    <affiliation>Taiwan Liposome Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Malignancy</keyword>
  <keyword>lymphoma</keyword>
  <keyword>TLC178</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

